Over-the-counter topical gel for periodontal disease management
ProEncia introduces an innovative line of patent-pending, non-invasive topical gel products designed to prevent, protect, and repair periodontal diseases. Validated through rigorous lab and clinical testing, these gels inhibit pathogen growth and support tissue repair, offering significant improvements in oral health.
Overview
ProEncia's innovative topical gel products address periodontal diseases by leveraging a unique formulation that acts on biological mechanisms to prevent and repair oral health issues. These products are designed to inhibit pathogen adherence and growth, thereby reducing plaque buildup and inflammation. Additionally, they promote tissue repair and immune system realignment, aiming to improve overall periodontal health.
Technical specifications
Key features:
- Pathogen Inhibition: The gels prevent critical biological functions necessary for pathogen growth and plaque formation, minimizing microbial virulence and inflammation.
- Immune Support & Tissue Repair: They enhance immune system function and aid in the repair and restoration of gum tissues, facilitating bone remodeling and periodontal strengthening.
- Validated Ingredients: Utilizing GRAS/GRASE safe list ingredients, the gels are designed for daily, long-term use, providing continuous oral health benefits.
- Versatile Integration: Can be easily incorporated into existing dental care products like toothpaste or mouthwash.
Technology readiness level
ProEncia's products have reached Technology Readiness Level 6, having been validated in lab settings and through clinical trials. The products demonstrated significant improvements in oral health markers, including reduced bleeding, sensitivity, and gum pocket depths in human trials. ProEncia seeks licensing and pilot trial engagements to further advance towards commercialization.
About ProEncia Biotechnology
ProEncia Biotechnology is a Minnesota-based biopharma startup founded in 2022 to develop innovative, non-invasive therapeutic products for the prevention and treatment of periodontal diseases. The company utilizes a patent-pending discovery platform that leverages small molecule combination medicine to create a synergistic therapeutic effect. This approach targets multiple biological mechanisms simultaneously, including the inhibition of critical pathogen functions, the reduction of microbial virulence factors, and the modulation of the host immune response to support tissue repair, alveolar bone remodeling, and overall gum health. Their pipeline consists of both over-the-counter preventive solutions and prescription-strength therapies designed to address various stages of severity, from gingivitis to chronic periodontitis.
These products are intended to fill a critical need in oral healthcare by providing more effective, accessible alternatives to current standard procedures like root scaling and planing. By managing both the pathogenic bacterial load and the associated systemic inflammatory response, ProEncia aims to improve clinical outcomes for patients suffering from persistent gum disease and its systemic health implications. The company has conducted in vitro studies demonstrating cellular regeneration and reduction of inflammation, as well as small-scale human trials indicating significant improvements in patient symptoms such as bleeding and gingival pocket depth. They are currently working toward the commercialization and licensing of their product line as they continue to advance their research and development efforts.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.